Prognosis and factors related to severe secondary hyperparathyroidism in long-term peritoneal dialysis patients

References

• Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):1–13.
   PubMed Web of Science ®Google Scholar
• Bouma-de Krijger A, Bots ML, Vervloet MG, et al. Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):88–97. doi: 10.1093/ndt/gft456.
   PubMed Web of Science ®Google Scholar
• Steinl GK, Kuo JH. Surgical management of secondary hyperparathyroidism. Kidney Int Rep. 2021;6(2):254–264. doi: 10.1016/j.ekir.2020.11.023.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Yu XQ, Yang JW, et al. Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study. Curr Med Res Opin. 2018;34(8):1491–1500. doi: 10.1080/03007995.2018.1467886.
   PubMed Web of Science ®Google Scholar
• Block GA, Cannataandia JB, Goldsmith D. Morbidity and mortality related to disturbances in mineral metabolism in CKD. 2nd ed. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease; 2010. p. 261–578.
   Google Scholar
• Pasnicu C, Radu PA, Garofil D, et al. Clinical aspects of parathyroid hyperplasia in secondary renal hyperparathyroidism. Chirurgia. 2019;114(5):594–601. doi: 10.21614/chirurgia.114.5.594.
   PubMed Web of Science ®Google Scholar
• Leifheit-Nestler M, Große Siemer R, Flasbart K, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31(7):1088–1099. doi: 10.1093/ndt/gfv421.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes 2017 clinical practice guideline update. Ann Intern Med. 2018;168(6):422–430. doi: 10.7326/M17-2640.
   PubMed Web of Science ®Google Scholar
• Saoposky D, Rown A, Dusso AJKI. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–S19.
   PubMedGoogle Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;S1–130. doi: 10.1038/ki.2009.188.
   Google Scholar
• Ali MS, Groenwold RH, Belitser SV, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. J Clin Epidemiol. 2015;68(2):112–121.
   PubMed Web of Science ®Google Scholar
• Mansournia MA, Altman DG. Inverse probability weighting. BMJ. 2016;352:i189. doi: 10.1136/bmj.i189.
   PubMedGoogle Scholar
• Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323(23):2417–2418. doi: 10.1001/jama.2020.7819.
   PubMed Web of Science ®Google Scholar
• Tabibzadeh N, Karaboyas A, Robinson BM, et al. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol Dial Transplant. 2021;36(1):160–169. doi: 10.1093/ndt/gfaa195.
   PubMed Web of Science ®Google Scholar
• Kirnap NG, Kirnap M, Sayin B, et al. Risk factors and treatment options for persistent hyperparathyroidism after kidney transplantation. Transplant Proc. 2020;52(1):157–161. doi: 10.1016/j.transproceed.2019.11.020.
   PubMed Web of Science ®Google Scholar
• Suwan N. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital. J Med Assoc Thailand. 2011;94(Suppl. 4):S101–S105.
   PubMedGoogle Scholar
• Akimbekov NS, Digel I, Sherelkhan DK, et al. Vitamin D and phosphate interactions in health and disease. Adv Exp Med Biol. 2022;1362:37–46. doi: 10.1007/978-3-030-91623-7_5.
   PubMedGoogle Scholar
• Morevati M, Mace ML, Egstrand S, et al. Extrarenal expression of α-klotho, the kidney related longevity gene, in Heterocephalus glaber, the long living naked mole rat. Sci Rep. 2021;11(1):15375. doi: 10.1038/s41598-021-94972-1.
   PubMed Web of Science ®Google Scholar
• Sun XM, Kong WX, Lu Y, et al. Different expressions of fibroblast growth factor receptor 1 (FGFR1) and Klotho in parathyroid cells with different hyperplasia from secondary hyperparathyroidism patients. Fudan Univ J Med Sci. 2018;45:823–829.
   Google Scholar
• Bover J, Ureña P, Ruiz-García C, et al. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2016;11(1):161–174. doi: 10.2215/CJN.01760215.
   PubMed Web of Science ®Google Scholar
• Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992;41(4):1049–1054. doi: 10.1038/ki.1992.159.
   PubMed Web of Science ®Google Scholar
• Hong-Mei Z, Qing-Dong X, Zhi-Hua Z, et al. Analysis of associated factors in secondary hyperparathyroidism of continuous ambulatory peritoneal dialysis patients. Chin J Nephrol. 2012;28:933–936.
   Google Scholar
• Rodriguez M, Canalejo A, Garfia B, et al. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl. 2002;61(80):155–160. doi: 10.1046/j.1523-1755.61.s80.26.x.
   Google Scholar
• Li Y, Ling Z, Pen L, et al. Evaluation of the efficacy of parathyroidectomy for refractory hyperparathyroidism in 89 cases. Chin J Blood Purif. 2009;8(8):431–436.
   Google Scholar
• Goldsmith D, Kothawala P, Chalian A, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis. 2009;53(6):1002–1013. doi: 10.1053/j.ajkd.2009.02.010.
   PubMed Web of Science ®Google Scholar
• Jorna FH, Tobé TJ, Huisman RM, et al. Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplant. 2004;19(5):1168–1173. doi: 10.1093/ndt/gfh018.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Bartsch DK, Sancho JJ, et al. Surgical management of secondary hyperparathyroidism in chronic kidney disease – a consensus report of the European Society of Endocrine Surgeons. Langenbecks Arch Surg. 2015;400(8):907–927. doi: 10.1007/s00423-015-1344-5.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Shilov E, Li Z, et al. Pattern of laboratory parameters and management of secondary hyperparathyroidism in countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020;37(6):2748–2762. doi: 10.1007/s12325-020-01359-1.
   PubMed Web of Science ®Google Scholar
• Chuang SH, Wong HC, Vathsala A, et al. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes. Singapore Med J. 2016;57(11):603–609. doi: 10.11622/smedj.2015195.
   PubMed Web of Science ®Google Scholar
• Francis DM, Busmanis I, Becker G. Peritoneal calcification in a peritoneal dialysis patient: a case report. Perit Dial Int. 1990;10(3):237–240. doi: 10.1177/089686089001000310.
   PubMed Web of Science ®Google Scholar
• Inoshita H, Gohda T, Io H, et al. Improvement of peritoneal calcification after parathyroidectomy in a peritoneal dialysis patient. Clin Nephrol. 2008;69(1):58–62. doi: 10.5414/cnp69058.
   PubMed Web of Science ®Google Scholar
• Huang JW, Lien YC, Yang CY, et al. High peritoneal Kt/V and peritonitis rates are associated with peritoneal calcification. PLOS One. 2013;8(8):e71636. doi: 10.1371/journal.pone.0071636.
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Bednarski D, Świderska M, et al. The calcium-sensing receptor gene polymorphism rs1801725 and calcium-related phenotypes in hemodialysis ­patients. Kidney Blood Press Res. 2018;43(3):719–734. doi: 10.1159/000489747.
   PubMed Web of Science ®Google Scholar
• Cheng SX, Lightfoot YL, Yang T, et al. Epithelial CaSR deficiency alters intestinal integrity and promotes proinflammatory immune responses. FEBS Lett. 2014;588(22):4158–4166. doi: 10.1016/j.febslet.2014.05.007.
   PubMed Web of Science ®Google Scholar
• Cheng SX. Calcium-sensing receptor: a new target for therapy of diarrhea. World J Gastroenterol. 2016;22(9):2711–2724. doi: 10.3748/wjg.v22.i9.2711.
   PubMed Web of Science ®Google Scholar